Facebook Instagram X-twitter Linkedin

Adipotide – 5mg

Table of Contents

  • Quickstart Highlights

Adipotide – 5mg protocols focus on this investigational peptide designed to target and reduce adipose (fat) tissue by inducing apoptosis in fat cell vasculature. By disrupting the blood supply to fat cells, Adipotide may support reductions in body fat mass and improvements in metabolic markers. This guide outlines a subcutaneous administration approach optimized for the 5 mg vial format.

  • Reconstitute: Add 1.0 mL bacteriostatic water → 5 mg/mL concentration
  • Typical daily range: 0.25–1 mg per day (subcutaneous)
  • Easy measuring: At 5 mg/mL, 1 unit = 0.01 mL = 50 mcg (0.05 mg) on a U-100 insulin syringe
  • Storage: Lyophilized: store at −20 °C; after reconstitution, refrigerate at 2–8 °C and use within 2–4 weeks
  • Protocol Overview

Concise summary of the subcutaneous regimen.

  • Goal: Support fat loss by targeting adipose tissue vasculature
  • Schedule: Daily subcutaneous injections in cycles
  • Dose Range: 0.25–1 mg per day
  • Cycle Length: Commonly used in short cycles (e.g., 2–4 weeks) followed by a break
  • Dosing Protocol

Suggested approach for the 5 mg vial format.

  • Start: 0.25 mg once daily to assess tolerance
  • Target: 0.5–1 mg once daily
  • Frequency: Once per day (subcutaneous)
  • Vial Duration: One 5 mg vial lasts approximately 5–20 days depending on dose
  • Timing: Morning administration often preferred; maintain consistent timing daily
  • Mechanism of Action

Adipotide is a synthetic peptide that targets specific receptors (such as prohibitin) expressed on the blood vessels supplying white adipose tissue. Once bound, it delivers a pro-apoptotic signal that disrupts the vasculature of fat cells.

By cutting off the blood supply, adipocytes (fat cells) undergo programmed cell death, leading to reductions in fat mass. This mechanism is distinct from traditional fat-loss approaches, as it directly targets fat tissue rather than relying solely on calorie restriction or metabolic stimulation. Preclinical studies have demonstrated significant fat loss and metabolic improvements in animal models.

  • Potential Benefits & Side Effects

Observations based on preclinical and early-stage research.

Potential Benefits:

  • May promote targeted reduction in body fat
  • May improve metabolic markers associated with obesity
  • Does not rely on appetite suppression or stimulant pathways
  • Potential support for weight management in controlled settings

Possible Side Effects:

  • Fatigue or mild lethargy during use
  • Injection-site irritation
  • Potential kidney-related stress observed in some animal studies
  • Requires careful dosing; long-term human safety data not established and remains investigational